Weight loss with GLP-1 or dual GIP/GLP-1 medicines such as semaglutide or tirzepatide usually comes mainly from fat, but absolute lean mass can also fall. Lean mass includes muscle, water, organs and other non-fat tissue, so it must not be relabelled automatically as “muscle loss.” InBody cannot assess the medicine’s safety; it can supplement repeated tracking of estimated muscle and fat alongside strength, function, nutrition and medical care.
GLP-1 medications are named after glucagon-like peptide-1, a hormone the body releases after eating that affects appetite, stomach emptying and blood sugar. The group includes active substances such as semaglutide and liraglutide, while the newer tirzepatide combines a GLP-1 and GIP effect. These medications were first used for type 2 diabetes and are now increasingly prescribed specifically for weight management.
The effect on body weight tends to be faster and larger than what most people experience with diet alone. Lower appetite and slower stomach emptying make it easier to eat less without the constant hunger many diets involve. That speed is part of why GLP-1 therapy has become so popular — and it is also exactly why the question of what is actually being lost along the way matters.
Trials of semaglutide and tirzepatide report reductions in both fat and lean mass. Meta-analyses also show that relative lean mass can be preserved or improve because fat generally falls more. A single claim such as “one quarter of weight loss is muscle” is therefore not a universal rule for every medicine or person.
Lean mass is not synonymous with skeletal muscle, and short-term changes also reflect water and glycogen. Functional context requires strength, everyday performance, food intake and activity alongside body-composition estimates.
Sarcopenia is not diagnosed from lean-mass kilograms alone. European consensus gives priority to low muscle strength and confirms the diagnosis with low muscle quantity or quality. Older, frail or rapidly losing patients need risk-based assessment by their clinical team.
A bathroom scale gives only total weight. InBody uses bioimpedance to estimate fat mass and skeletal muscle mass separately, so repeated trends can be followed. It does not directly image muscle, and early changes may partly reflect water or glycogen.
A more favorable trend is usually one in which fat accounts for most of the loss while strength and estimated muscle are preserved as well as possible. A repeated fall in estimated muscle, strength or function should prompt a review with the clinical team, not an independent medication change.
Two people who lose the same five kilograms over the same period can end up in very different places, depending on what that weight loss is actually made of. The comparison below illustrates two simplified patterns for the same amount of scale weight lost.
| Metric | Fat-dominant weight loss | Weight loss with notable muscle loss |
|---|---|---|
| Fat mass | Drops clearly and makes up most of the loss. | Drops, but is not the only part of the loss. |
| Muscle mass | Stays roughly stable. | Drops noticeably alongside fat. |
| Resting energy expenditure | Estimated BMR may fall less if fat-free mass is preserved. | Estimated BMR may fall more if estimated fat-free mass falls. |
| What to add beyond InBody | Strength, activity, protein intake and everyday function. | Strength, activity, intake, symptoms and clinical review. |
A joint professional advisory emphasizes adequate high-quality food and protein, prevention of very low energy or micronutrient intake, and risk-based monitoring. A safe target cannot be derived from body weight alone; age, kidney function, treatment tolerance and the clinical plan matter.
More protein alone is unlikely to preserve muscle without resistance or strength exercise. Training must be adapted to baseline function, joints, symptoms and access; a generic weekly target is a goal to individualize, not a condition for medication safety.
Persistent vomiting, inability to eat or drink adequately, rapid functional decline or signs of dehydration need clinical review. Supplements such as creatine do not replace nutrition, training or medical monitoring.
For results to be comparable, measurements should happen under similar conditions — a similar time of day, similar hydration, no training right before the test. That matters for any InBody tracking, but it matters more during rapid weight loss, because more is changing in the body at once.
Measurement frequency should match the pace of change, not the urge to check constantly. During faster weight loss, checking roughly every few weeks is usually enough to catch an unwanted muscle trend early, without turning small fluctuations between visits into unnecessary worry.
The result history in the client portal is useful here, since it lines up measurements over time and shows how the fat and muscle curves move together, rather than comparing only the last two results in isolation. A longer timeline makes it much easier to tell a real trend apart from normal variation between visits.
InBody does not evaluate the safety or suitability of GLP-1 treatment, does not assess dosing, and does not replace lab work or follow-up with the prescribing doctor. It is a supporting tool for tracking body composition alongside medical care, not instead of it.
If muscle mass is clearly dropping faster than fat, or you notice significant fatigue, dizziness, loss of strength in everyday tasks or other unusual symptoms, talk to your doctor rather than waiting for the next InBody measurement. The same applies to any decision about adjusting or stopping the medication — that is always a decision for the prescribing doctor, not something to conclude from a result sheet.
About the measurement
The main page about body composition measurement, result output and the visit.
More reading
FAQ
Trials show a fall in lean mass alongside the larger fall in fat. Lean mass is not identical to muscle and also includes water and other tissue. Repeated composition estimates should be interpreted with strength, function, nutrition and medical context.
A regular scale cannot tell you, since it only shows total weight change. You need a method that separates fat mass from muscle mass, such as InBody, and to track both over repeated measurements taken under similar conditions.
Resistance exercise and adequate protein are leading supportive strategies, but the size of their effect during GLP-1 treatment and the right plan vary. Targets should be adapted to health status and the prescribing team’s guidance.
No. InBody is a supporting tool for tracking body composition, not a replacement for medical monitoring, lab tests or dose adjustments. Decisions about the treatment itself always belong to the prescribing doctor.
During faster weight loss, checking roughly every few weeks is usually enough to catch an unwanted muscle-loss trend early, without letting small fluctuations between visits lead to premature conclusions.
Sources
During GLP-1-supported weight loss, repeated estimates of fat and muscle matter more than one scale number. InBody can show the direction of those estimates; grip strength and everyday function add information that bioimpedance cannot measure.